Screener
Praxis Precision Medicines, Inc. PRAX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001689548-26-000083
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 96,904 | 76,067 | 202,764 | 150,795 |
| Loss from operations | (96,904) | (76,067) | (202,764) | (150,795) |
| Other income: | ||||
| Other income, net | 13,184 | 4,940 | 26,483 | 10,372 |
| Total other income | 13,184 | 4,940 | 26,483 | 10,372 |
| Net loss | $(83,720) | $(71,127) | $(176,281) | $(140,423) |
| Net loss per share attributable to common stockholders, basic and diluted | $(2.87) | $(3.31) | $(6.08) | $(6.60) |
| Weighted average common shares outstanding, basic and diluted | 29,131,375 | 21,474,827 | 29,008,351 | 21,266,490 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Praxis Precision Medicines, Inc.'s business segments — net loss?
- Praxis Precision Medicines, Inc. (PRAX) reported business segments — net loss of -$83.72M in Q2 2026.
- How has Praxis Precision Medicines, Inc.'s business segments — net loss changed year-over-year?
- Praxis Precision Medicines, Inc.'s business segments — net loss decreased by 17.7% year-over-year, from -$71.13M to -$83.72M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s business segments — net loss?
- Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s business segments — net loss has grown at a 56.8% compound annual growth rate (CAGR), from -$123.28M to -$303.27M.
- What does business segments — net loss mean?
- This metric represents the bottom-line financial result for the business segment, calculated as total revenues minus total expenses. For a clinical-stage company, this typically reflects the significant investment in R&D relative to limited revenue generation. It is the primary indicator of the segment's financial sustainability and cash burn.
Ask your AI about Praxis Precision Medicines, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude